Safety of RG2077 in Patients With Multiple Sclerosis

NCT00076934 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: RG2077 (CTLA4-IgG4m)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]